Atypical hemolytic-uremic syndrome in a patient with adenosine deaminase deficiency

Anne Pham-Huy^a, Vy Hong-Diep Kim^b, Elizabeth Nizalik^c, Gabrielle Weiler^d, Jennifer Vethamuthu^d, and Eyal Grunebaum^{b*}

ABSTRACT

Inherited defects in the ubiquitous adenosine deaminase (ADA) enzyme disrupt the function of the immune system as well as many other organs and tissues. Some patients may also suffer from kidney damage. Here we report on an ADA-deficient patient who was treated with ADA replacement therapy from infancy and at 6 years of age developed acute kidney failure, thrombocytopenia, and severe anemia. A kidney biopsy demonstrated mesangiolysis and occlusion of kidney loops by erythrocytes and platelet aggregates, which is consistent with hemolytic-uremic syndrome (HUS). There was no evidence of exposure to Shiga toxins, nor were any complement abnormalities detected. The kidney function improved following hemodialysis. Our report demonstrates the increased susceptibility of ADA-deficient patients to develop HUS and expands the nonimmune abnormalities associated with ADA deficiency. This further emphasizes the vigilance required when caring for such patients.

Statement of novelty: Here we provide the first detailed clinical and histological characterization of hemolytic-uremic syndrome developing in an ADA-deficient patient.

Introduction

Adenosine deaminase (ADA) is a ubiquitous enzyme that catalyzes the deamination of adenosine and deoxyadenosine to inosine and 2'-deoxyinosine, respectively. Inherited defects that disrupt ADA enzyme activity lead to marked lymphopenia, resulting in severe immune deficiency with increased susceptibility to bacterial, viral, and opportunistic infections, typically in infancy (Grunebaum et al. 2013). ADA-deficient patients may also develop various autoimmune features, including autoimmune cytopenia, possibly due to abnormalities in regulatory T cells (Sauer et al. 2012). Treatment options for ADA deficiency include hematopoietic stem cell transplantation (HSCT), preferably from a

human leukocyte antigen (HLA)-identical sibling donor. In the absence of an appropriate donor for HSCT, experimental gene therapy or repeated injections of polyethylene glycol conjugated-ADA (PEG-ADA) can be used (Gaspar et al. 2009). Long-term survival with ADA enzyme replacement is possible, although many patients remain susceptible to infections, autoimmunity, and malignancy (Husain et al. 2007). ADA is ubiquitously expressed; therefore, it is not surprising that impaired ADA activity also disrupts many other cells, tissues, and organs including hepatocytes, chondrocytes, osteoblasts, alveolar macrophages, etc. (Bollinger et al. 1996; Grunebaum et al. 2012). ADA deficiency can also affect patients' bone marrow (Sokolic et al. 2011) and kidneys (Ratech et al. 1985).

^aDivision of Pediatric Infectious Diseases, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; ^bDivision of Immunology and Allergy, Hospital for Sick Children, Toronto, ON, Canada; ^cDepartment of Pathology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; ^dDivision of Pediatric Nephrology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada

Submitted 2 June 2015
Accepted 15 July 2015
Available online 21 July 2015

*Correspondence: Eyal Grunebaum/eyal.grunebaum@sickkids.ca

LymphoSign Journal 2:195–199 (2015)
dx.doi.org/10.14785/lpsn-2015-0010

Hemolytic-uremic syndrome (HUS) is the most common cause of acute kidney failure in children, affecting 0.2–4.2 children per 100 000 children worldwide. HUS is characterized by progressive kidney failure, nonimmune (Coombs-negative) microangiopathic hemolytic anemia, and thrombocytopenia. HUS is most often associated with a Shiga-like toxin produced by enterohemorrhagic *E. coli* O157:H7. Rarer cases have also been known to be triggered by neuraminidase-producing *Streptococcus pneumoniae* (Brandt et al. 2002), although HUS unrelated to toxins, often categorized as atypical HUS, is being recognized at an increasing frequency (Keir and Coward 2011). Kidney biopsies from patients suffering from HUS often show vascular wall thickening as well as swelling and detachment of the endothelial cells from the basement membrane. Additionally, there is an accumulation of material in the subendothelial space, intraluminal platelet thrombosis, partial or complete vessel luminal obstruction, and fragmentation of red blood cells (Keir and Coward 2011). Here we describe an ADA-deficient patient who developed atypical HUS.

Case report

The Institutional Research Ethics Board at The Hospital for Sick Children, Toronto, approved the study and a written informed consent for the research was obtained. The female patient, born to Inuit nonconsanguineous parents, was identified in infancy as suffering from ADA deficiency based on absent ADA activity in the erythrocytes and the identification of compound heterozygous mutations in the ADA gene (c.424C> T and c.955_959delGAAGA). An HLA-matched donor for HSCT could not be found; therefore, the patient was treated with PEG-ADA (ADAGEN®) resulting in a very limited immune reconstitution (Table 1). The patient also received prophylactic sulfamethoxazole/thrimethoprim and monthly intravenous immunoglobulin (IVIG) infusions without significant infections or autoimmunity. Sensorineural hearing loss was noted in infancy and stage I hypertension, that didn't require treatment, was observed in early childhood. Kidney function and ultrasound were reported to be normal.

At 6 years of age the patient was admitted following a 2-week history of vomiting, fatigue, and increased bruising with normal urine output and no diarrhea. The patient had received IVIG 3 weeks earlier, was reported to have recovered from a mild upper respiratory tract infection, and had normal complete blood count, kidney

Table 1: Patient's laboratory findings.

	At diagnosis	Maximal	Latest
White blood cells $\times 10^9/L$	1.9	6.0	9.3
Neutrophils $\times 10^9/L$	1.2	3.4	8.1
Lymphocytes $\times 10^9/L$	0.1	2.2	0.2
CD3+CD4+ $\times 10^9/L$	0.02	0.2	0.02
CD3+CD8+ $\times 10^9/L$	0.00	0.11	0.01
CD19+ $\times 10^9/L$	0.01	1.2	0.07
CD16+/56+ $\times 10^9/L$	0.06	0.6	0.06
ADA activity in plasma (nmol·min ⁻¹ ·mL ⁻¹)	Undetectable	589	528

functions, and urine. Upon admission, the patient was afebrile and normotensive. Initial laboratory investigations revealed markedly elevated creatinine 500 $\mu\text{mol/L}$ (normal 9–55 $\mu\text{mol/L}$), urea 50 mmol/L (normal 3.0–7.0 mmol/L), and phosphate 3.08 mmol/L (normal 1.30–1.75 mmol/L) as well as low hemoglobin 49 g/L (normal 105–135 g/L) and ionized calcium 0.69 mmol/L (normal 1.10–1.30 mmol/L) with normal coagulation. Blood gas revealed the patient's pH was 7.49 with a base excess of 12.9 mmol/L. Urinalysis showed 2+ blood and protein. All microbiology studies were negative. There was an *E. coli* O157:H7 outbreak occurring in the patient's community 2 months prior to her presentation. However there was no known direct contact of the patient with affected individuals nor was Shiga-toxin producing *E. coli* isolated from the patient's stools at the time of her acute presentation. All viral cultures (nasopharyngeal and stool) as well as blood cultures remained negative. There was also no history of ingestion of ethylene glycol, methanol, drugs, or other toxins. The patient was treated briefly with ceftriaxone and piperacillin-tazobactam. After 3 days in hospital, she developed nonbloody diarrhea and thrombocytopenia (nadir of $84 \times 10^9/L$), which resolved after 2 days. A kidney biopsy revealed mesangiolytic and replication of the basement membrane with insudation of plasma into the mesangium and into the glomerular capillary wall (Figure 1A). There was also thickening of the loops with narrowing and occlusion of the loops by the replicated basement membrane, matrix, and cells (Figure 1B). Some loops were occluded by erythrocytes and platelet aggregates (Figure 1C). Electron microscopy confirmed the glomerular mesangiolytic and the accumulation of a pale matrix within the glomerular basement membrane (GBM) with elevation of the endothelial cells and replication of the GBM (Figure 1D). These features were consistent with a thrombotic microangiopathy. There was no evidence

Figure 1: Kidney biopsy from an adenosine deaminase deficient patient who developed atypical hemolytic uremic syndrome. Glomerulus with mesangiolytic and tram-tracking. Periodic Schiff-methenamine staining, $\times 60$ (A). Semi-thin section with glomerulus with mesangiolytic and accumulation of pale matrix within the glomerular basement membrane (GBM) with elevation of the endothelial cells and replication of the GBM. Toluidine blue staining, $\times 60$ (B). Glomerulus with capillary loops stuffed with erythrocytes, plasma, and platelets. Narrowing of some capillary lumens. Hematoxylin-phloxine-safranin staining, $\times 60$ (C). Electron micrograph with glomerular mesangiolytic and accumulation of pale matrix within the GBM with elevation of the endothelial cells and GBM replication, $\times 12\,000$ (D).

of tubulo-interstitial nephritis. The patient was treated by hemodialysis, with improved kidney function and normalization of the serum creatinine and urea. PEG-ADA and IVIG administration were not interrupted. C3 and C4 levels were within the normal range. ADAMTS13 (von Willebrand factor-cleaving protease) testing was negative. Mutations in genes coding for proteins involved in regulation or activation of the alternative complement activation pathway including factor H, I, membrane cofactor protein, and factor B or C3 were not identified. Antibodies to complement components or Factor H were not detected. Thus, the ADA-deficient patient described here has unequivocal clinical, laboratory, and histological characteristics of HUS with significant kidney disease.

Discussion

Abnormal kidney function and histology, including accumulation of mesangial fibrillar matrix (mesangial

sclerosis), obliterated glomeruli, and thickened capillary subendothelial layer were previously described in 6 ADA-deficient patients (Ratech et al. 1985). However, clinical details of the patients and whether they exhibited features of HUS were not provided (Ratech et al. 1985). Recently, 4 additional ADA-deficient patients with moderate to severe acute kidney failure, hemolytic anemia, and thrombocytopenia requiring dialysis or plasmapheresis were reported (Table 2). These patients were identified as suffering from atypical HUS, although detailed kidney histology was not provided (Nikolajeva et al. 2015). Hence, our patient is the first where the diagnosis of HUS is further supported by histological findings. Interestingly, the patient described here had early hypertension, albeit mild, several years before the development of HUS. Also, reminiscent of the findings in our patient, kidneys from ADA-deficient mice also display substantial red blood cell increase in the glomeruli and convoluted tubules (Blackburn et al. 1998) as well as decreased capillary lumen and mesangial hypercellularity (Dai et al. 2011) that could be prevented by

Table 2: Characteristics of 5 ADA-deficient patients diagnosed with HUS.

Feature	No. of patients
Female	2
HUS after the first year of life	3
Preceding infection	2
Preceding PEG-ADA treatment	2
Severe renal failure requiring dialysis or plasmapheresis	5
Moderate to severe thrombocytopenia and hemolytic anemia	5
Significant complement (C3 and C4) abnormalities	0
Survived the acute event	3
Residual renal injury	3

Note: The 5 patients include the patient reported here and patients reported previously (Nikolajeva et al. 2015).

correction of the metabolic abnormalities. Cumulatively, the data presented here suggest contribution of the ADA defect to the development of kidney damage and HUS.

The pathogenesis of HUS in ADA-deficient patients is intriguing. It is unlikely that significant infections or autoimmunity were the culprit, as these conditions often do not resolve spontaneously in immune-compromised hosts. It is also unlikely that PEG-ADA caused kidney failure, even though it is a foreign protein, as only 1 of the 4 ADA-deficient patients previously reported with HUS had received PEG-ADA prior to the kidney damage (Table 2). Moreover, kidney function improved in our patient while she continued to receive PEG-ADA. Similarly, the ethnic diversity of the ADA-deficient patients suggests that the HUS was not caused by defects in other genes such as the complement gene family. Alternatively, it is possible that an intercurrent infection or post-infectious process reported in our patient and others exacerbated pre-existing kidney injury. We did not identify Shiga toxin *E. coli* O157 or evidence of pneumococcal infection in our patient. Regardless of the pathogenesis and somewhat reassuring, prompt intervention with dialysis reversed the kidney failure leading to improved kidney function.

In conclusion, our report demonstrates increased susceptibility of ADA-deficient patients for the development of HUS, expands the nonimmune abnormalities associated with ADA deficiency, and further emphasizes the vigilance required when caring for these patients.

Acknowledgements

EG is supported by the Donald and Audrey Campbell Chair for Immunology research.

REFERENCES

Blackburn, M.R., Datta, S.K., and Kellems, R.E. 1998. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. *J. Biol. Chem.* **273** (9):5093–5100. PMID: 9478961. doi: 10.1074/jbc.273.9.5093.

Bollinger, M.E., Arredondo-Vega, F.X., Santisteban, I., Schwarz, K., Hershfield, M.S., and Lederman, H.M. 1996. Brief report: Hepatic dysfunction as a complication of adenosine deaminase deficiency. *N. Engl. J. Med.* **334**(21):1367–1371. PMID: 8614422. doi: 10.1056/NEJM199605233342104.

Brandt, J., Wong, C., Mihm, S., Roberts, J., Smith, J., Brewer, E., Thiagarajan, R., and Warady, B. 2002. Invasive pneumococcal disease and hemolytic uremic syndrome. *Pediatrics.* **110**(2):371–376. PMID: 12165593. doi: 10.1542/peds.110.2.371.

Dai, Y., Zhang, W., Wen, J., Zhang, Y., Kellems, R.E., and Xia, Y. 2011. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. *J. Am. Soc. Nephrol.* **22**(5):890–901. PMID: 21511827. doi: 10.1681/ASN.2010080890.

Gaspar, H.B., Aiuti, A., Porta, F., Candotti, F., Hershfield, M.S., and Notarangelo, L.D. 2009. How I treat ADA deficiency. *Blood.* **114**(17):3524–3532. PMID: 19638621. doi: 10.1182/blood-2009-06-189209.

Grunebaum, E., Cohen, A., and Roifman, C. M. 2013. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. *Curr. Opin. Allergy Clin. Immunol.* **13**(6):630–638. PMID: 24113229. doi: 10.1097/ACI.0000000000000006.

Grunebaum, E., Cutz, E., and Roifman, C.M. 2012. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. *J. Allergy Clin. Immunol.* **129**(6):1588–1593. PMID: 22409989. doi: 10.1016/j.jaci.2012.02.003.

Husain, M., Grunebaum, E., Naqvi, A., Atkinson, A., Ngan, B.Y., Aiuti, A., and Roifman, C.M. 2007. Burkitt’s lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. *J. Pediatr.* **151**(1):93–95. PMID: 17586199.

Keir, L., and Coward, R.J. 2011. Advances in our understanding of the pathogenesis of glomerular

- thrombotic microangiopathy. *Pediatr. Nephrol.* **26**(4):523–533. PMID: 20949284. doi: 10.1007/s00467-010-1637-4.
- Nikolajeva, O., Worth, A., Hague, R., Martinez-Alier, N., Smart, J., Adams, S., Davies, E.G., and Gaspar, H.B. 2015. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome. *J. Clin. Immunol.* **35**(4):366–372. PMID: 25875700. doi: 10.1007/s10875-015-0158-0.
- Ratech, H., Greco, M.A., Gallo, G., Rimoin, D.L., Kamino, H., and Hirschhorn, R. 1985. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. *Am. J. Pathol.* **120**(1):157–169. PMID: 4014441.
- Sauer, A.V., Brigida, I., Carriglio, N., and Aiuti, A. 2012. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. *Front Immunol.* **3**:265. PMID: 22969765. doi: 10.3389/fimmu.2012.00265.
- Sokolic, R., Maric, I., Kesserwan, C., Garabedian, E., Hanson, I.C., Dodds, M., Buckley, R., Issekutz, A.C., Kamani, N., Shaw, K., Tan, B., Bali, P., Hershfield, M.S., Kohn, D.B., Wayne, A.S., and Candotti, F. 2011. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. *Blood.* **118**(10):2688–2694. PMID: 21725047. doi: 10.1182/blood-2011-01-329359.